Sourav Bandyopadhyay, PhD

Professor
Department of Bioengineering and Therapeutic Sciences
Bandyopadhyay
[email protected]
Phone: +1 415 476-3425
1450 Third Street, Rm 001
UCSF Box 0128
San Francisco, CA 94158
United States

Links

UCSF Profiles Bandyopadhyay Lab

Affiliations

Education programs

Pharmaceutical Sciences and Pharmacogenomics Graduate Program (PSPG)
Biological and Medical Informatics Graduate Program (BMI)

UCSF centers, institutes, and research programs

Associate Director, Quantitative Biosciences Institute (QBI)
Coleader, Molecular Oncology Program

What I do

I seek to understand, at the systems level, how biological networks within cancer cells are fundamentally different from those in normal cells. Using a variety of experimental techniques, I design new platforms for the rational application of personalized medicine and the design of combination cancer therapies.

Departmental research area

computational biology and systems pharmacology

Professional background

Degrees

Bioinformatics and Systems Biology, University of California, San Diego, 2010
Computer Science & Molecular Biology, University of Wisconsin, 2002

Biography

Sourav Bandyopadhyay obtained his PhD in Bioinformatics and Systems Biology with Trey Ideker (UC San Diego) where he made seminal contributions to our understanding of the organization and plasticity of physical and genetic interaction networks, (Bandyopadhyay et al. Science 2010, Nature Methods 2010, PLoS Computational Biology 2008). In 2010 he began an independent research career through the prestigious UCSF faculty fellowship designed to provide early independence to the world’s best scientists.

The Bandyopadhyay lab employs new cellular and molecular technologies to tackle the most urgent and clinically important problems in cancer therapy, including functional genomics, drug screens, proteomics and single cell approaches. Critically, these technologies often generate the scale and complexity of data that necessitate the development of new computational algorithms to maximize their impact and fully understand their relevance in the clinic. The lab is focused on identifying mechanisms of drug resistance and targetable synthetic lethal interactions in breast and lung cancers since these diseases are deadly in the metastatic setting and demonstrate suboptimal tumor responses even with out best, most targeted therapies. We are committed to the identification, mechanistic dissection and clinical translation of new targets and target combinations through broad collaborations with biotechnologists, chemists, clinicians and pharma.

Research keywords

  • networks
  • Cancer Biology
  • precision medicine
  • pathways
  • bioinformatics
  • pharmacogenomics
  • systems biology
  • pharmacogenetics
  • Protein Interaction Mapping
  • Protein Kinase Inhibitors
  • Gene Regulatory Networks
  • Aurora Kinase A
  • Drug Resistance, Neoplasm
  • Breast Neoplasms
  • Cell Line, Tumor
  • Azepines
  • Plant Proteins
  • Antineoplastic Agents
  • Epistasis, Genetic
  • Synthetic Lethal Mutations
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Triple Negative Breast Neoplasms

Publications

Turnham RE, Pitea A, Jang GM, Xu Z, Lim HC, Choi AL, Von Dollen J, Levin RS, Webber JT, McCarthy E, Hu J, Li X, Che L, Singh A, Yoon A, Chan G, Kelley RK, Swaney DL, Zhang W, Bandyopadhyay S, Theis FJ, Eckhardt M, Chen X, Shokat KM, Ideker T, Krogan NJ, Gordan JD. HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. Cancer Res. 2024 Dec 09.
Haderk F, Chou YT, Cech L, Fernández-Méndez C, Yu J, Olivas V, Meraz IM, Barbosa Rabago D, Kerr DL, Gomez C, Allegakoen DV, Guan J, Shah KN, Herrington KA, Gbenedio OM, Nanjo S, Majidi M, Tamaki W, Pourmoghadam YK, Rotow JK, McCoach CE, Riess JW, Gutkind JS, Tang TT, Post L, Huang B, Santisteban P, Goodarzi H, Bandyopadhyay S, Kuo CJ, Roose JP, Wu W, Blakely CM, Roth JA, Bivona TG. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer. Nat Commun. 2024 May 03; 15(1):3741.
Donghwa Kim, Dmitry Kuchenov, Aubhishek Zaman, Neal Bennett, Emilio Ramos, Ken Nakamura, Arun P. Wiita, Sourav Bandyopadhyay, Trever Bivona. Abstract 4653: Unraveling the vulnerabilities of targeted therapy-tolerant persister cells in NSCLC. Cancer Research. 2024 Mar 22; 84(6_Supplement):4653-4653.
Jacobo Jacobo M, Donnella HJ, Sobti S, Kaushik S, Goga A, Bandyopadhyay S. An inflamed tumor cell subpopulation promotes chemotherapy resistance in triple negative breast cancer. Sci Rep. 2024 02 14; 14(1):3694.
Yu K, Basu A, Yau C, Wolf DM, Goodarzi H, Bandyopadhyay S, Korkola JE, Hirst GL, Asare S, DeMichele A, Hylton N, Yee D, Esserman L, van 't Veer L, Sirota M. Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes. Front Oncol. 2023; 13:1192208.
Meng D, Zhao X, Yang YC, Navickas A, Helland C, Goodarzi H, Singh M, Bandyopadhyay S. A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer. Oncogene. 2023 Jul; 42(28):2207-2217.
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Res. 2022 Sep 02; 82(17):3187.
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Res. 2022 Sep 02; 82(17):3188.
Kim SH, Song JH, Kim MJ, Song MG, Ku AA, Bandyopadhyay S, McCormick F, Kim SE. Novel Regulators of Macropinocytosis-Dependent Growth Revealed by Informer Set Library Screening in Pancreatic Cancer Cells. Metabolites. 2022 Sep 02; 12(9).
John Gordan, Adriana Pitea, Rigney E Turnham, Manon Eckhardt, Gwendolyn M Jang, Huat Lim, Alex L Choi, Sourav Bandyopadhyay, Danielle Swaney, Kevan Shokat, Trey Ideker, Nevan Krogan. Abstract PO017: HBV alters YAP regulation in liver cancer by remodeling PP2A complexes. Clinical Cancer Research. 2022 Sep 1; 28(17_Supplement):po017-po017.
Wong DR, Conrad J, Johnson N, Ayers J, Laeremans A, Lee JC, Lee J, Prusiner SB, Bandyopadhyay S, Butte AJ, Paras NA, Keiser MJ. Trans-channel fluorescence learning improves high-content screening for Alzheimer's disease therapeutics. Nat Mach Intell. 2022 Jun; 4(6):583-595.
Wolfe AL, Zhou Q, Toska E, Galeas J, Ku AA, Koche RP, Bandyopadhyay S, Scaltriti M, Lebrilla CB, McCormick F, Kim SE. UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth. Proc Natl Acad Sci U S A. 2021 08 03; 118(31).
Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Wechsler EI, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2021 Jul 15; 27(14):4129.
Collin M. Blakely, Matthew A. Gubens, Gregory M. Allen, Shrusti Shah, Matthew Jereza, Bianca Bacaltos, Sourav Bandyopadhyay. Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):9074-9074.
Kim D, Bandyopadhyay S. Aurora kinases shed light on resistance to EGFR inhibition in head and neck cancer. EBioMedicine. 2021 03; 65:103257.
Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL. Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. Mol Cancer Ther. 2020 11; 19(11):2382-2395.
Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. 2020 09 03; 182(5):1232-1251.e22.
Andrew L. Wolfe, Jacqueline Galeas, Eneda Toska, Qing Zhou, Angel Ku, Richard P. Koche, Sourav Bandyopadhyay, Carlito B. Lebrilla, Maurizio Scaltriti, Frank McCormick, Sung Eun Kim. Abstract 1470: UGP2 is a critical regulator of protein glycosylation in pancreatic cancer. Cancer Research. 2020 Aug 15; 80(16_Supplement):1470-1470.
Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. J Invest Dermatol. 2021 02; 141(2):364-373.
Ku AA, Hu HM, Zhao X, Shah KN, Kongara S, Wu D, McCormick F, Balmain A, Bandyopadhyay S. Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility. Nat Commun. 2020 05 12; 11(1):2375.
F. Haderk, C. Fernández-Méndez, K.N. Shah, W. Wu, J. Guan, J. Rotow, D. Allegakoen, V. Olivas, S. Bandyopadhyay, C. Kuo, T. Bivona. B01 Active YAP as a Functional Marker of Drug-Tolerant Persister Cells in EGFR-Mutant and ALK Fusion-Positive NSCLC. Journal of Thoracic Oncology. 2020 Feb 1; 15(2):s27.
CHI-HENG WU, Chen-Yen Yang, Linlin Wang, Hua-Xin Gao, Rakhshandehroo Taha, Shervin Afghani, Laura Pincus, Ronald Balassanian, James Rubenstein, Ryan Gill, Sourav Bandyopadhyay, Frank McCormick, Mark Moasser, Weiyun Z. Ai. Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models. Blood. 2019 Nov 13; 134(Supplement_1):1578-1578.
Khyati N. Shah, Roma Bhatt, Julia Rotow, Julia Rohrberg, Victor Olivas, Victoria E. Wang, Jonathan Kuhn, Sophie Dumont, Frank Mccormick, Andrei Goga, Collin M. Blakely, Trever G. Bivona, Sourav Bandyopadhyay. Abstract 2902: Non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC. Tumor Biology. 2019 Jul 1; 2902-2902.
Shah KN, Bandyopadhyay S. Targeting the evolution of drug resistance in lung cancer. Mol Cell Oncol. 2019; 6(5):e1603092.
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019 01; 25(1):111-118.
Webber JT, Kaushik S, Bandyopadhyay S. Integration of Tumor Genomic Data with Cell Lines Using Multi-dimensional Network Modules Improves Cancer Pharmacogenomics. Cell Syst. 2018 11 28; 7(5):526-536.e6.
K. Shah, C. Blakely, T. Bivona, S. Bandyopadhyay. P1.13-10 Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer. Journal of Thoracic Oncology. 2018 Oct 1; 13(10):s585-s586.
Hayley Donnella, James Webber, Kevan Shokat, Andrei Goga, John Gordan, Sourav Bandyopadhyay. Abstract A45: Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer. Resistance Mechanisms. 2018 Aug 1; a45-a45.
Khyati N. Shah, Roma Bhatt, Julia Rotow, Julia Rohrberg, Victor Olivas, Golzar Golzar Hemmati, Gregor Krings, Henry J. Haringsma, Andrew D. Simmons, Thomas C. Harding, Andrei Goga, Collin Blakely, Trever Bivona, Sourav Bandyopadhyay. Abstract 1957: Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Experimental and Molecular Therapeutics. 2018 Jul 1; 1957-1957.
Swati Kaushik, Gwendolyn Jang, Hsien-Ming Hu, Khyati Shah, Xin Zhao, John Jascur, John Von Dollen, Erik Verschueren, Jeffrey Johnson, Nevan Krogan, Sourav Bandyopadhyay. Abstract 3297: A tyrosine kinase interactome reveals network states that guide the use of targeted therapies in cancer. Bioinformatics and Systems Biology. 2018 Jul 1; 3297-3297.
Chi-Heng Wu, Chen-Yen Yang, Taha Rakhshandhroo, Laura Pincus, Sourav Bandyopadhyay, Frank McCormick, Weiyun Ai. Abstract 798: Pathway-directed high-throughput drug screen identifies PI3K inhibitors that synergistically potentiate antitumor activity of HDAC inhibitors in cutaneous T-cell lymphoma. Experimental and Molecular Therapeutics. 2018 Jul 1; 798-798.
Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S. Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nat Chem Biol. 2018 08; 14(8):768-777.
Hu HM, Zhao X, Kaushik S, Robillard L, Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC, Bandyopadhyay S. A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Rep. 2018 Apr 17; 23(3):918-929.
Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR. Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Res. 2018 05 01; 78(9):2383-2395.
Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA. Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 2018 01 23; 7.
Toni M. Brand, Stefan Hartmann, Neil E. Bhola, Hua Li, Yan Zeng, Rachel O'Keefe, Max V. Ranall, Sourav Bandyopadhyay, Margaret Soucheray, Danielle L. Swaney, Nevan Krogan, Carolyn Kemp, Umamaheswar Duvvuri, Daniel E. Johnson, Michelle A. Ozbun, Julie E. Bauman, Jennifer R. Grandis. Abstract PR04: HER3 crosstalk with HPV16-E6E7 is a feedback resistance mechanism to PI3K-targeted therapies in head and neck cancer. Viral Cancers HPV/EBV. 2017 Dec 1; pr04-pr04.
Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2017 Jun 15; 23(12):3072-3083.
Webber JT, Ranall MV, Kaushik S, Bandyopadhyay S.. Connecting tumor genomics with therapeutics through multi-dimensional network modules. BioArxiv. 2016.
Kohnz RA, Roberts LS, DeTomaso D, Bideyan L, Yan P, Bandyopadhyay S, Goga A, Yosef N, Nomura DK. Protein Sialylation Regulates a Gene Expression Signature that Promotes Breast Cancer Cell Pathogenicity. ACS Chem Biol. 2016 08 19; 11(8):2131-9.
Toni Michel Brand, Stefan Hartmann, Neil Bhola, Noah D. Peyser, Hua Li, Yan Zeng, Max V. Randall, Sourav Bandyopadhyay, Jennifer R. Grandis. Abstract 1205: HER3 is a functional molecular target in HPV-associated head and neck cancer. Experimental and Molecular Therapeutics. 2016 Jul 15; 1205-1205.
Chen-Yen Yang, Razan Faraj, Taha Rakhshandaroo, Shervin Afghani, Laura Pincus, Sourav Bandyopadhyay, Frank McCormick, Weiyun Ai. Abstract 388: Pathway-directed high throughput drug screen identifies PI3K inhibitors that synergistically potentiate anti-tumor activity of HDAC inhibitors in mycosis fungoides and Sézary syndrome. Experimental and Molecular Therapeutics. 2016 Jul 15; 388-388.
Hofree M, Carter H, Kreisberg JF, Bandyopadhyay S, Mischel PS, Friend S, Ideker T. Challenges in identifying cancer genes by analysis of exome sequencing data. Nat Commun. 2016 07 15; 7:12096.
Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. Mol Cancer Ther. 2016 07; 15(7):1472-84.
Susan Samson, Alicia Y. Zhou, Maria Martins, Alexandra Corella, Dai Horiuchi, Christina Yau, Taha Rakshandehroo, John Gordan, Rebecca Levin, Jeff Johnson, John Jascur, Mike Shales, Antonio Sorrentino, Jaime Cheah, Paul Clemens, Alykhan Shamji, Stuart Schreiber, Nevan Krogan, Kevan Shokat, Frank McCormick, Sourav Bandyopadhyay, Andrei Goga. Abstract C88: Genomics, advocacy, and emerging therapeutics to address triple-negative breast cancer (TNBC) outcome disparities. Community Groups and Advocacy. 2016 Mar 1; c88-c88.
Weiyun Ai, Chen-Yen Yang, Razan Faraj, Taha Rakhshandhroo, Shervin Afghani, Laura Pincus, Sourav Bandyopadhyay, Frank McCormick. Pathway-Directed High Throughput Drug Screen Identifies PI3K Inhibitors That Synergistically Potentiate Anti-Tumor Activity of HDAC Inhibitors in Mycosis Fungoides and Sezary Syndrome. Blood. 2015 Dec 3; 126(23):2755-2755.
Maria M. Martins, Alicia Y. Zhou, Alexandra Corella, Dai Horiuchi, Christina Yau, Taha Rakshandehroo, John D. Gordan, Rebecca S. Levin, Jeff Johnson, John Jascur, Mike Shales, Antonio Sorrentino, Jaime Cheah, Paul A. Clemons, Alykhan Shamji, Stuart Schreiber, Stuart Schreiber, Nevan J. Krogan, Kevan M. Shokat, Kevan M. Shokat, Frank McCormick, Daniel Nomura, Sourav Bandyopadhyay, Andrei Goga. Abstract PR07: Functional analysis of diverse oncogenic driver mutations using an isogenic cell line library identifies novel drug responses and alterations in metabolism. Network-Based Cancer Biology. 2015 Nov 15; pr07-pr07.
Maria M. Martins, Alicia Y. Zhou, Alexandra Corella, Dai Horiuchi, Christina Yau, Taha Rakshandehroo, John D. Gordan, Rebecca S. Levin, Jeff Johnson, John Jascur, Mike Shales, Antonio Sorrentino, Jaime Cheah, Paul A. Clemons, Alykhan Shamji, Stuart Schreiber, Stuart Schreiber, Nevan J. Krogan, Kevan M. Shokat, Kevan M. Shokat, Frank McCormick, Daniel Nomura, Sourav Bandyopadhyay, Andrei Goga. Abstract PR15: Functional analysis of diverse oncogenic driver mutations using an isogenic cell line library identifies novel drug responses and alterations in metabolism. Network-Based Cancer Biology. 2015 Nov 15; pr15-pr15.
Alicia Y. Zhou, Maria M. Martins, Alexandra Corella, Dai Horiuchi, Christina Yau, Taha Rakshandehroo, John D. Gordan, Rebecca S. Levin, Jeff Johnson, John Jascur, Mike Shales, Antonio Sorrentino, Jaime Cheah, Paul A. Clemons, Alykhan Shamji, Stuart Schreiber, Nevan J. Krogan, Kevan M. Shokat, Frank McCormick, Susan Samson, Andrei Goga, Sourav Bandyopadhyay. Abstract B44: A systems approach combining genomics, advocacy, and emerging novel therapeutics to address triple-negative breast cancer (TNBC) outcomes disparities. Organ Site Research. 2015 Oct 1; b44-b44.
Alicia Y. Zhou, Maria M. Martins, Alexandra Corella, Dai Horiuchi, Christina Yau, Taha Rakshandehroo, John D. Gordan, Rebecca S. Levin, Jeff Johnson, John Jascur, Mike Shales, Antonio Sorrentino, Jaime Cheah, Paul A. Clemons, Alykhan Shamji, Stuart L. Schreiber, Nevan J. Krogan, Kevan M. Shokat, Frank McCormick, Andrei Goga, Sourav Bandyopadhyay. Abstract B48: Identification of novel drug interactions with MYC via a quantitative chemical-genetic interaction map. Therapeutic Translation. 2015 Oct 1; b48-b48.
Kristopher A. Sarosiek, Alison Karst, Peter Winter, Antonio Sorrentino, Sourav Bandyopadhyay, Andrei Goga, Kris C. Wood, Ronny Drapkin, Anthony Letai. Abstract 970: Broad therapy resistance is induced by suppression of apoptotic priming by lineage programs and oncogenic activation. Molecular and Cellular Biology. 2015 Aug 1; 970-970.
Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, Ruggero D, McCormick F. Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions. Cancer Res. 2015 Jul 15; 75(14):2851-62.
Kohnz RA, Mulvihill MM, Chang JW, Hsu KL, Sorrentino A, Cravatt BF, Bandyopadhyay S, Goga A, Nomura DK. Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer. ACS Chem Biol. 2015 Jul 17; 10(7):1624-30.
Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 07; 11(1):98-110.
Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakhshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov. 2015 02; 5(2):154-67.
M. Sos, R.S. Levin, J.D. Gordan, J.A. Oses-Prieto, J.T. Webber, M. Salt, B. Hann, A.L. Burlingame, F. McCormick, S. Bandyopadhyay, K.M. Shokat. 73 Differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer. European Journal of Cancer. 2014 Nov 1; 50:28-29.
Steve Braunstein, Rana Mroue, Brian Huang, Sourav Bandyopadhyay, Jean Nakamura. Abstract 68: Tumor operational signaling pathways in an Nf1 mutant mouse model system. Cancer Research. 2014 Oct 1; 74(19_Supplement):68-68.
Martin L. Sos, Rebecca Levin, John Gordan, Juan Oses-Prieto, James Webber, Megan Salt, Byron Hann, Alma Burlingame, Frank Mccormick, Sourav Bandyopadhyay, Kevan Shokat. Abstract LB-216: Integrated analysis of differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancer. Experimental and Molecular Therapeutics. 2014 Oct 1; lb-216-lb-216.
Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 2014 Aug 21; 8(4):1037-48.
Benjamin DI, Louie SM, Mulvihill MM, Kohnz RA, Li DS, Chan LG, Sorrentino A, Bandyopadhyay S, Cozzo A, Ohiri A, Goga A, Ng SW, Nomura DK. Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness. ACS Chem Biol. 2014 Jun 20; 9(6):1340-50.
Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona TG. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):E748-57.
Salt MB, Bandyopadhyay S, McCormick F. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 2014 Feb; 4(2):186-99.
S.E. Braunstein, R. Mroue, B. Huang, S. Bandyopadhyay, J. Nakamura. Operational Signaling Pathways in Radiation-Induced Tumors. International Journal of Radiation Oncology • Biology • Physics. 2013 Oct 1; 87(2):s627.
Bushman FD, Barton S, Bailey A, Greig C, Malani N, Bandyopadhyay S, Young J, Chanda S, Krogan N. Bringing it all together: big data and HIV research. AIDS. 2013 Mar 13; 27(5):835-8.
Roguev A, Talbot D, Negri GL, Shales M, Cagney G, Bandyopadhyay S, Panning B, Krogan NJ. Quantitative genetic-interaction mapping in mammalian cells. Nat Methods. 2013 May; 10(5):432-7.
Bandyopadhyay S, Mehta M, Kuo D, Sung MK, Chuang R, Jaehnig EJ, Bodenmiller B, Licon K, Copeland W, Shales M, Fiedler D, Dutkowski J, Guénolé A, van Attikum H, Shokat KM, Kolodner RD, Huh WK, Aebersold R, Keogh MC, Krogan NJ, Ideker T. Rewiring of genetic networks in response to DNA damage. Science. 2010 Dec 03; 330(6009):1385-9.
Kuo D, Licon K, Bandyopadhyay S, Chuang R, Luo C, Catalana J, Ravasi T, Tan K, Ideker T. Coevolution within a transcriptional network by compensatory trans and cis mutations. Genome Res. 2010 Dec; 20(12):1672-8.
Bandyopadhyay S, Chiang CY, Srivastava J, Gersten M, White S, Bell R, Kurschner C, Martin C, Smoot M, Sahasrabudhe S, Barber DL, Chanda SK, Ideker T. A human MAP kinase interactome. Nat Methods. 2010 Oct; 7(10):801-5.
König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, Bhattacharyya S, Alamares JG, Tscherne DM, Ortigoza MB, Liang Y, Gao Q, Andrews SE, Bandyopadhyay S, De Jesus P, Tu BP, Pache L, Shih C, Orth A, Bonamy G, Miraglia L, Ideker T, García-Sastre A, Young JA, Palese P, Shaw ML, Chanda SK. Human host factors required for influenza virus replication. Nature. 2010 Feb 11; 463(7282):813-7.
Fossum E, Friedel CC, Rajagopala SV, Titz B, Baiker A, Schmidt T, Kraus T, Stellberger T, Rutenberg C, Suthram S, Bandyopadhyay S, Rose D, von Brunn A, Uhlmann M, Zeretzke C, Dong YA, Boulet H, Koegl M, Bailer SM, Koszinowski U, Ideker T, Uetz P, Zimmer R, Haas J. Evolutionarily conserved herpesviral protein interaction networks. PLoS Pathog. 2009 Sep; 5(9):e1000570.
Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, Diamond TL, Zhou H, Hazuda DJ, Espeseth AS, König R, Bandyopadhyay S, Ideker T, Goff SP, Krogan NJ, Frankel AD, Young JA, Chanda SK. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog. 2009 May; 5(5):e1000437.
Wilmes GM, Bergkessel M, Bandyopadhyay S, Shales M, Braberg H, Cagney G, Collins SR, Whitworth GB, Kress TL, Weissman JS, Ideker T, Guthrie C, Krogan NJ. A genetic interaction map of RNA-processing factors reveals links between Sem1/Dss1-containing complexes and mRNA export and splicing. Mol Cell. 2008 Dec 05; 32(5):735-46.
König R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT, Chiang CY, Tu BP, De Jesus PD, Lilley CE, Seidel S, Opaluch AM, Caldwell JS, Weitzman MD, Kuhen KL, Bandyopadhyay S, Ideker T, Orth AP, Miraglia LJ, Bushman FD, Young JA, Chanda SK. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell. 2008 Oct 03; 135(1):49-60.
Roguev A, Bandyopadhyay S, Zofall M, Zhang K, Fischer T, Collins SR, Qu H, Shales M, Park HO, Hayles J, Hoe KL, Kim DU, Ideker T, Grewal SI, Weissman JS, Krogan NJ. Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. Science. 2008 Oct 17; 322(5900):405-10.
Bandyopadhyay S, Kelley R, Krogan NJ, Ideker T. Functional maps of protein complexes from quantitative genetic interaction data. PLoS Comput Biol. 2008 Apr 18; 4(4):e1000065.
Beyer A, Bandyopadhyay S, Ideker T. Integrating physical and genetic maps: from genomes to interaction networks. Nat Rev Genet. 2007 Sep; 8(9):699-710.
Bandyopadhyay S, Sharan R, Ideker T. Systematic identification of functional orthologs based on protein network comparison. Genome Res. 2006 Mar; 16(3):428-35.
Bandyopadhyay S, Kelley R, Ideker T. Discovering regulated networks during HIV-1 latency and reactivation. Pac Symp Biocomput. 2006; 354-66.
Canet-Avilés RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, Baptista MJ, Ringe D, Petsko GA, Cookson MR. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A. 2004 Jun 15; 101(24):9103-8.
Bandyopadhyay S, Cookson MR. Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol. 2004 Feb 19; 4:6.